-
Mashup Score: 1
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 3Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history - 7 month(s) ago
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Personal View: #Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia5S6d #diabetes #obesity #SGLT2 inhibitors #GLP-1 receptor agonists
-
-
Mashup Score: 8SGLT‐2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies - 7 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @EJHFEiC: #SGLT2-i in #HF: towards decongestion and beyond... Pleiotropic effects of #gliflozines in #HF. https://t.co/uuKyXLoZfZ @HFA…
-
-
Mashup Score: 15
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 13Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction - 8 month(s) ago
Abstract. For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibito
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
The sodium-glucose cotransporter2 inhibitors are robust, disease-modifying therapies in heart failure with preserved ejection fraction. Discover the mechanisms of benefits of #SGLT2 in #HF with preserved EF in #EHJ https://t.co/WnCblvPH9X #cardiotwitter @ESC_Journals @escardio https://t.co/la4BYLJ5Ee
-
iSGLT2 en #insuficienciacardiaca con fracción de eyección preservada. Cuáles son los mecanismos que explican su beneficio? Artículo de revisión en @ESC_Journals https://t.co/odvt7pNyRW https://t.co/HdwaO4bQdP
-
-
Mashup Score: 0EMPACT-MI: Is Preventing HF After Heart Attack the Next Frontier for SGLT2 Inhibitors? - 8 month(s) ago
Javed Butler, MD, MPH, MBA, said “hopefully” results from the EMPACT-MI trial should be available within the next few months.
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Is preventing #HeartFailure after a heart attack the next frontier for #SGLT2 Inhibitors? Here's what Javed Butler, MD, MPH, MBA, says about the #EMPACT-MI trial, which should be available within the next few months! Learn more: https://t.co/6PU2hzVfUC
-
-
Mashup Score: 4
A meta-analysis of three trials assessing the use of SGLT2 inhibitors for inpatients with COVID-19 showed the drug class did not reduce risk for death or other outcomes compared with usual care or placebo, but was safe.“The fundamental pathobiology of COVID-19 infection and organ damage includes many pathophysiologic properties that, at least theoretically, could be impacted in a favorable
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A meta-analysis of 3 trials of #SGLT2 inhibitors for inpatients with #COVID19 showed they did not reduce risk for death/other outcomes vs. usual care or placebo, but was safe @MkosiborodMD @InfectDisNews @MidAmericaHeart #ESCCongress #cardiotwitter https://t.co/wc5uPhkvdb
-
-
Mashup Score: 2
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 2GLP-1 Agonists May Reduce Adverse CV Event Risk Regardless of SGLT2 Inhibitor Use in Patients with TD2, CVD: Post Hoc Analysis - 9 month(s) ago
In patients with type 2 Diabetes (T2D) and cardiovascular disease, treatment with a GLP-1 receptor agonist (GLP-1 RA) reduces the risk of adverse cardiovascular events independently of background sodi
Source: www.crtonline.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In patients with type 2 #Diabetes & #CVD, treatment with GLP-1 RA decreases the risk of adverse CV events independently of background #SGLT2 use, according to findings in #JACC. https://t.co/Rp3tHPZi9t @CRT_meeting
-
-
Mashup Score: 9
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD